<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A02B&quot;,&quot;href&quot;:&quot;atc/A02B.md&quot;},{&quot;label&quot;:&quot;lansoprazole&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Lansoprazole_Katashima1995_reference&quot;,&quot;label&quot;:&quot;Katashima_1995_reference&quot;,&quot;href&quot;:&quot;drugs/drug_lansoprazole/Lansoprazole_Katashima1995_reference.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Lansoprazole_Sakurai2007_1_compartment&quot;,&quot;label&quot;:&quot;Sakurai_2007_1_compartment&quot;,&quot;href&quot;:&quot;drugs/drug_lansoprazole/Lansoprazole_Sakurai2007_1_compartment.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Lansoprazole_Sakurai2007_2_compartment&quot;,&quot;label&quot;:&quot;Sakurai_2007_2_compartment&quot;,&quot;href&quot;:&quot;drugs/drug_lansoprazole/Lansoprazole_Sakurai2007_2_compartment.md&quot;,&quot;status&quot;:&quot;rejected&quot;,&quot;css&quot;:&quot;pk-badge--red&quot;,&quot;here&quot;:false}]"></div>

# lansoprazole

- **generic name:** lansoprazole
- **ATC codes:** `A02BC03`
- **DrugBank:** [DB00448](https://go.drugbank.com/drugs/DB00448) · **PubChem:** [CID 3883](https://pubchem.ncbi.nlm.nih.gov/compound/3883)
- **molar mass:** 369.361 g/mol (C16H14F3N3O2S) — DrugBank
- **groups:** approved, investigational

## About

**Description.** Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole.[A177065] It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion.[A177053]

**Indication.** Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. [A4892][A177065][FDA Label]  It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis.[FDA Label] Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. [FDA Label]  Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. [FDA Label]  Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy). [FDA Label]

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-29 21:43 | 5:46 | 0/2/1 | 0/2/0 | 0/0/0 | 55,575/19,385 | ollama / qwen3.8:27b-mtp-q8_0 | 13 | 12/1 | 4/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.286). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: disposition incomplete — only clearance/elimination extracted — the engineer ne…</sub><br><sub>route_to: `human_review`</sub> | [Katashima_1995_reference](drugs/drug_lansoprazole/Lansoprazole_Katashima1995_reference.md) | — | 1-compartment (no model) | 1 | Katashima M et al., Comparative pharmacokinetic/pharmacodyn…, Drug metabolism and disposi… (1995) | — |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (partly confirmed, agreement 0.857). The first reading is what the record holds.">cross-check: partial</span><br><sub>blocking: no distribution volume and no clearance/elimination — not a compartmental popPK…</sub><br><sub>blocking: C5 dimension mismatch on a structural parameter</sub><br><sub>route_to: `human_review`</sub> | [Sakurai_2007_1_compartment](drugs/drug_lansoprazole/Lansoprazole_Sakurai2007_1_compartment.md) | — | 1-compartment (no model) | 2 | Sakurai Y et al., Population pharmacokinetics and proton…, Biological & pharmaceutical… (2007) | [10.1248/bpb.30.2238](https://doi.org/10.1248/bpb.30.2238) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (partly confirmed, agreement 0.857). The first reading is what the record holds.">cross-check: partial</span><br><sub>blocking: no distribution volume and no clearance/elimination — not a compartmental popPK…</sub><br><sub>blocking: C5 dimension mismatch on a structural parameter</sub><br><sub>route_to: `human_review`</sub> | [Sakurai_2007_2_compartment](drugs/drug_lansoprazole/Lansoprazole_Sakurai2007_2_compartment.md) | — | 1-compartment (no model) | 2 | Sakurai Y et al., Population pharmacokinetics and proton…, Biological & pharmaceutical… (2007) | [10.1248/bpb.30.2238](https://doi.org/10.1248/bpb.30.2238) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.0). The first reading is what the record holds.">cross-check: partial</span> | [Menzel_2005_CYP35A1](drugs/drug_lansoprazole/pd_Menzel_2005_CYP35A1.md) | CYP35A1 mRNA expression ← unknown · stimulation effect | — | Menzel R et al., CYP35: xenobiotically induced gene expr…, Archives of biochemistry an… (2005) | [10.1016/j.abb.2005.03.020](https://doi.org/10.1016/j.abb.2005.03.020) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.0). The first reading is what the record holds.">cross-check: partial</span> | [Menzel_2005_CYP35A2](drugs/drug_lansoprazole/pd_Menzel_2005_CYP35A2.md) | CYP35A2 mRNA expression ← unknown · stimulation effect | — | Menzel R et al., CYP35: xenobiotically induced gene expr…, Archives of biochemistry an… (2005) | [10.1016/j.abb.2005.03.020](https://doi.org/10.1016/j.abb.2005.03.020) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.0). The first reading is what the record holds.">cross-check: partial</span> | [Menzel_2005_CYP35A5](drugs/drug_lansoprazole/pd_Menzel_2005_CYP35A5.md) | CYP35A5 mRNA expression ← unknown · stimulation effect | — | Menzel R et al., CYP35: xenobiotically induced gene expr…, Archives of biochemistry an… (2005) | [10.1016/j.abb.2005.03.020](https://doi.org/10.1016/j.abb.2005.03.020) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.0). The first reading is what the record holds.">cross-check: partial</span> | [Menzel_2005_CYP35C1](drugs/drug_lansoprazole/pd_Menzel_2005_CYP35C1.md) | CYP35C1 mRNA expression ← unknown · stimulation effect | — | Menzel R et al., CYP35: xenobiotically induced gene expr…, Archives of biochemistry an… (2005) | [10.1016/j.abb.2005.03.020](https://doi.org/10.1016/j.abb.2005.03.020) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.75). The first reading is what the record holds.">cross-check: disputed</span> | [Menzel_2005_Reproduction](drugs/drug_lansoprazole/pd_Menzel_2005_Reproduction.md) | Reproduction ← unknown · stimulation effect | — | Menzel R et al., CYP35: xenobiotically induced gene expr…, Archives of biochemistry an… (2005) | [10.1016/j.abb.2005.03.020](https://doi.org/10.1016/j.abb.2005.03.020) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.0). The first reading is what the record holds.">cross-check: partial</span> | [Wu_2019_intragastric_pH](drugs/drug_lansoprazole/pd_Wu_2019_intragastric_pH.md) | name ← dexlansoprazole · inhibition effect | — | Wu L et al., Pharmacokinetic/Pharmacodynamic Evaluat…, Clinical drug investigation (2019) | [10.1007/s40261-019-00824-2](https://doi.org/10.1007/s40261-019-00824-2) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.0). The first reading is what the record holds.">cross-check: partial</span> | [Wu_2019_percentage_of_time_with_intragastric_pH_above_4_0](drugs/drug_lansoprazole/pd_Wu_2019_percentage_of_time_with_intragastric_pH_above_4_0.md) | name ← dexlansoprazole · inhibition effect | — | Wu L et al., Pharmacokinetic/Pharmacodynamic Evaluat…, Clinical drug investigation (2019) | [10.1007/s40261-019-00824-2](https://doi.org/10.1007/s40261-019-00824-2) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.0). The first reading is what the record holds.">cross-check: partial</span> | [Wu_2019_percentage_of_time_with_intragastric_pH_above_6_0](drugs/drug_lansoprazole/pd_Wu_2019_percentage_of_time_with_intragastric_pH_above_6_0.md) | name ← dexlansoprazole · inhibition effect | — | Wu L et al., Pharmacokinetic/Pharmacodynamic Evaluat…, Clinical drug investigation (2019) | [10.1007/s40261-019-00824-2](https://doi.org/10.1007/s40261-019-00824-2) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=lansoprazole) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | blood-brain barrier | `ABCB1` inhibitor/substrate, `ABCG2` inhibitor | DrugBank actor |
| absorption | kidney | `ABCB1` inhibitor/substrate | DrugBank actor |
| absorption | liver | `ABCB1` inhibitor/substrate, `ABCG2` inhibitor | DrugBank actor |
| absorption | mammary gland | `ABCG2` inhibitor | DrugBank actor |
| absorption | placenta | `ABCB1` inhibitor/substrate | DrugBank actor |
| absorption | small intestine | `ABCB1` inhibitor/substrate, `ABCG2` inhibitor | DrugBank actor |
| absorption | testis | `ABCB1` inhibitor/substrate, `ABCG2` inhibitor | DrugBank actor |
| distribution | liver | `SLC22A3` unknown | DrugBank actor |
| distribution | placenta | `SLC22A3` unknown | DrugBank actor |
| distribution | skeletal muscle | `SLC22A3` unknown | DrugBank actor |
| metabolism | brain | `CYP2D6` inhibitor | DrugBank actor |
| metabolism | liver | `CYP2C19` inhibitor/substrate, `CYP2C8` substrate, `CYP2C9` inducer/inhibitor, `CYP2D6` inhibitor, `CYP3A4` inducer/inhibitor/substrate, `SLC22A1` unknown | DrugBank actor |
| metabolism | lung | `CYP1A1` inducer, `CYP1B1` inducer | DrugBank actor |
| metabolism | skin | `CYP1B1` inducer | DrugBank actor |
| metabolism | small intestine | `CYP1A1` inducer, `CYP3A4` inducer/inhibitor/substrate | DrugBank actor |
| excretion | kidney | `SLC22A2` unknown, `SLC22A8` inhibitor | DrugBank actor |

<sub>Actors without a tissue in the table: ATP4A (inhibitor), CYP2C18 (substrate), MAPT (binder).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 20 matched, 19 returned
- **screened:** 15  ·  **relevant:** 6
- **records:** 3  ·  extracted 0  ·  needs_review 1  ·  rejected 2  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_6 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Helfer_2025.pdf` | Helfer VE et al., Exploring the Influence of Obesity and…, Clinical pharmacokinetics (2025) | popPK | 10 | [10.1007/s40262-025-01517-0](https://doi.org/10.1007/s40262-025-01517-0) | [40379961](https://pubmed.ncbi.nlm.nih.gov/40379961) | The paper describes a population PK model for lansoprazole, but the specific numeric parameter values (CL, V, etc.) are not present in the provided abstract text. |
| `Hu_2004.pdf` | Hu YR et al., Pharmacokinetics of lansoprazole in Chi…, Acta pharmacologica Sinica (2004) | popPK | 10 | not captured | [15301728](https://pubmed.ncbi.nlm.nih.gov/15301728) | The paper reports quantitative pharmacokinetic parameters (Cl/F, T1/2, Cmax, AUC) for lansoprazole in human subjects, and all numeric values are explicitly present in the provided text. |
| `Tran_2002.pdf` | Tran A et al., Pharmacokinetic-pharmacodynamic study o…, Clinical pharmacology and t… (2002) | popPK | 10 | [10.1067/mcp.2002.122472](https://doi.org/10.1067/mcp.2002.122472) | [12011821](https://pubmed.ncbi.nlm.nih.gov/12011821) | The study reports quantitative pharmacokinetic parameters (clearance, volume of distribution, half-life) for lansoprazole in children, with all numeric values explicitly present in the text. |
| `Katashima_1995.pdf` | Katashima M et al., Comparative pharmacokinetic/pharmacodyn…, Drug metabolism and disposi… (1995) | popPK | 9 | not captured | [7587960](https://pubmed.ncbi.nlm.nih.gov/7587960) | The study reports quantitative pharmacokinetic parameters (clearance, volume of distribution) for lansoprazole in rats, with specific numeric values provided in the text. |
| `Zalloum_2012.pdf` | Zalloum I et al., Genetic polymorphism of CYP2C19 in a Jo…, Molecular biology reports (2012) | popPK | 9 | [10.1007/s11033-011-1204-5](https://doi.org/10.1007/s11033-011-1204-5) | [21769476](https://pubmed.ncbi.nlm.nih.gov/21769476) | The study reports quantitative non-compartmental pharmacokinetic parameters (Tmax, Cmax, t1/2, AUC) for lansoprazole in a human population, with values explicitly listed in the text. |
| `Alai_2014.pdf` | Alai M et al., Novel lansoprazole-loaded nanoparticles…, The AAPS journal (2014) | popPK | 8 | [10.1208/s12248-014-9564-0](https://doi.org/10.1208/s12248-014-9564-0) | [24519468](https://pubmed.ncbi.nlm.nih.gov/24519468) | The study is a pharmacokinetic evaluation of lansoprazole nanoparticles in vivo, but the provided evidence contains only qualitative descriptions and efficacy percentages, lacking specific numeric PK parameters like clearance or volume. |

<sub>queue written 2026-09-29T21:39:42.193201+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Alai_2014 | relevant | 8 | 0 | The study is a pharmacokinetic evaluation of lansoprazole nanoparticles in vivo, but the provided evidence contains only qualitative descriptions and efficacy percentages, lacking specific numeric PK parameters like clearance or volume. |
| PD | Alai_2014 | not_relevant | 2 | 1 | The paper reports PK data (sustained concentration) and a qualitative/percentage-based efficacy outcome (ulcer healing rate) but does not provide numeric PD parameters (e.g., Emax, EC50) or a quantitative concentration-effect model. |
| popPK | Echizen_2016_2 | irrelevant | 0 | 0 | The paper focuses on the pharmacokinetics of vonoprazan, with lansoprazole serving only as a comparator agent for potency and acid suppression. |
| popPK | Helfer_2025 | relevant | 10 | 0 | The paper describes a population PK model for lansoprazole, but the specific numeric parameter values (CL, V, etc.) are not present in the provided abstract text. |
| popPK | Katashima_1998 | irrelevant | 2 | 0 | The study reports PK/PD parameters (reaction rate constants, turnover rates) rather than standard disposition parameters (CL, V, ka) for lansoprazole. |
| popPK | Kirchheiner_2009_2 | irrelevant | 0 | 0 | The paper is a pharmacodynamic meta-analysis focusing on dose-dependent intragastric pH effects and relative potency, not a pharmacokinetic study reporting disposition parameters like clearance or volume for lansoprazole. |
| popPK | Litalien_2005 | irrelevant | 2 | 0 | The text is a review summarizing general PK characteristics (e.g., half-life ~1 hour) without providing specific quantitative parameter values (CL, V, ka) for lansoprazole. |
| popPK | Liu_2005 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of CYP2C9 activation by lansoprazole enantiomers and does not report pharmacokinetic disposition parameters (CL, V, ka, etc.) for lansoprazole. |
| popPK | Menzel_2005 | irrelevant | 0 | 0 | The study is a toxicological and gene expression analysis in C. elegans using lansoprazole as a xenobiotic inducer, and it does not report any pharmacokinetic parameters (CL, V, ka, etc.) for the drug. |
| popPK | Ollier_2015 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of dabigatran, with lansoprazole serving only as a comparator in an in-vitro efflux assay and not as the subject drug for PK parameter estimation. |
| popPK | Prinz_1994 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of gastrin effects on ECL cells where lansoprazole is only used as a negative control, with no pharmacokinetic parameters reported. |
| PD | Prinz_1994 | not_relevant | 0 | 0 | The paper reports that lansoprazole did not affect BrdU incorporation in isolated ECL cells, providing no numeric PD parameters or exposure-response relationship for the drug. |
| popPK | Puchalski_2001 | irrelevant | 2 | 0 | The study focuses on pharmacodynamic modeling of gastric pH and reports PD parameters (e.g., enzyme inactivation constant) rather than quantitative pharmacokinetic disposition parameters (CL, V, ka) for lansoprazole. |
| popPK | Thota_2013 | irrelevant | 2 | 0 | The study is a bioequivalence trial using non-compartmental analysis (Cmax, AUC, T1/2) rather than a population PK study reporting compartmental parameters (CL, V, Q, ka), and no specific numeric values are provided in the evidence. |
| popPK | Wang_2026 | irrelevant | 2 | 0 | The study reports non-compartmental bioequivalence parameters (Cmax, AUC) and relative changes due to food, but does not provide quantitative disposition parameters like clearance (CL), volume (V), or half-life (t1/2) required for population PK modeling. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-18 05:29 UTC</sub>
